FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285384608> ?p ?o ?g. }

• W4285384608 endingPage "21" @default.
• W4285384608 startingPage "14" @default.
• W4285384608 abstract "No biomarkers are recommended for patients undergoing radiation-based therapy (RT) for muscle-invasive bladder cancer (MIBC). We aim to evaluate the predictive role of programmed death-ligand 1 (PD-L1) expression on the oncological outcomes of patients treated with RT for MIBC. A single-center retrospective analysis of tumor specimens collected through transurethral resection (TURBT) from 104 MIBC patients, implemented in a tissue microarray and stained with the SP263 PD-L1 clone (Ventana Medical Systems, Tucson, AZ, USA), was conducted. Two reviewers measured the PD-L1 H-score for tumor and immune cells. RT (maximal TURBT followed by radiation and concurrent chemotherapy when eligible). Logistic and Cox regression models were used to predict 3-mo complete response (CR) and overall survival (OS) after RT, respectively. A total of 88 (85%) patients had cT2 disease and 39 (37.5%) had high immune cell PD-L1 expression. A CR was achieved in 68 (65%) patients. On the multivariable analysis (MVA), a higher clinical stage (p = 0.02) and a low immune cell PD-L1 H-score (p = 0.02) were associated with a decreased CR after RT. The median time to death was 43 mo (95% confidence interval 20–66). On Cox MVA, a high immune cell PD-L1 H-score (p = 0.0017) was associated with better OS, independently of performance status (p = 0.0005) or tumor stage (p = 0.0013). A high tumor cell PD-L1 H-score was not an independent predictor of CR or OS. Limitations of the study include the retrospective design. MIBC patients with high PD-L1 expression on immune cells appear to have better oncological outcomes following RT. Our results may aid in patient stratification for future clinical trial design. In this report, we evaluated the role of programmed death-ligand 1 (PD-L1) expressed on tumor and immune cells in the tumor microenvironment for patients treated with a bladder-sparing regimen. We found that PD-L1 overexpression on immune cells is able to predict a better response to radiation-based therapy." @default.
• W4285384608 created "2022-07-14" @default.
• W4285384608 creator A5006809964 @default.
• W4285384608 creator A5018230672 @default.
• W4285384608 creator A5020232745 @default.
• W4285384608 creator A5023126884 @default.
• W4285384608 creator A5024741202 @default.
• W4285384608 creator A5027492028 @default.
• W4285384608 creator A5055368367 @default.
• W4285384608 creator A5055910619 @default.
• W4285384608 creator A5090305989 @default.
• W4285384608 creator A5091337701 @default.
• W4285384608 date "2022-09-01" @default.
• W4285384608 modified "2023-10-02" @default.
• W4285384608 title "Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy" @default.
• W4285384608 cites W1966628829 @default.
• W4285384608 cites W1972882573 @default.
• W4285384608 cites W1975848770 @default.
• W4285384608 cites W1983093014 @default.
• W4285384608 cites W1983648619 @default.
• W4285384608 cites W2035660473 @default.
• W4285384608 cites W2036777171 @default.
• W4285384608 cites W2071183770 @default.
• W4285384608 cites W2073571081 @default.
• W4285384608 cites W2090241022 @default.
• W4285384608 cites W2113156769 @default.
• W4285384608 cites W2128422065 @default.
• W4285384608 cites W2140310677 @default.
• W4285384608 cites W2143772132 @default.
• W4285384608 cites W2145623483 @default.
• W4285384608 cites W2147476574 @default.
• W4285384608 cites W2150780222 @default.
• W4285384608 cites W2161765043 @default.
• W4285384608 cites W2269750828 @default.
• W4285384608 cites W2462649057 @default.
• W4285384608 cites W2570190993 @default.
• W4285384608 cites W2588916311 @default.
• W4285384608 cites W2607471882 @default.
• W4285384608 cites W2609787832 @default.
• W4285384608 cites W2611893941 @default.
• W4285384608 cites W2612383893 @default.
• W4285384608 cites W2633073200 @default.
• W4285384608 cites W2742288460 @default.
• W4285384608 cites W2777192533 @default.
• W4285384608 cites W2792856868 @default.
• W4285384608 cites W2807701194 @default.
• W4285384608 cites W2904713531 @default.
• W4285384608 cites W2917900760 @default.
• W4285384608 cites W2921292930 @default.
• W4285384608 cites W2940349477 @default.
• W4285384608 cites W2985932098 @default.
• W4285384608 cites W3023288864 @default.
• W4285384608 cites W3092900114 @default.
• W4285384608 cites W3093554611 @default.
• W4285384608 cites W3136760947 @default.
• W4285384608 cites W3162694534 @default.
• W4285384608 doi "https://doi.org/10.1016/j.euros.2022.06.009" @default.
• W4285384608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36353066" @default.
• W4285384608 hasPublicationYear "2022" @default.
• W4285384608 type Work @default.
• W4285384608 citedByCount "1" @default.
• W4285384608 countsByYear W42853846082023 @default.
• W4285384608 crossrefType "journal-article" @default.
• W4285384608 hasAuthorship W4285384608A5006809964 @default.
• W4285384608 hasAuthorship W4285384608A5018230672 @default.
• W4285384608 hasAuthorship W4285384608A5020232745 @default.
• W4285384608 hasAuthorship W4285384608A5023126884 @default.
• W4285384608 hasAuthorship W4285384608A5024741202 @default.
• W4285384608 hasAuthorship W4285384608A5027492028 @default.
• W4285384608 hasAuthorship W4285384608A5055368367 @default.
• W4285384608 hasAuthorship W4285384608A5055910619 @default.
• W4285384608 hasAuthorship W4285384608A5090305989 @default.
• W4285384608 hasAuthorship W4285384608A5091337701 @default.
• W4285384608 hasBestOaLocation W42853846081 @default.
• W4285384608 hasConcept C121608353 @default.
• W4285384608 hasConcept C126322002 @default.
• W4285384608 hasConcept C126894567 @default.
• W4285384608 hasConcept C143998085 @default.
• W4285384608 hasConcept C146357865 @default.
• W4285384608 hasConcept C151730666 @default.
• W4285384608 hasConcept C151956035 @default.
• W4285384608 hasConcept C167135981 @default.
• W4285384608 hasConcept C203014093 @default.
• W4285384608 hasConcept C2776694085 @default.
• W4285384608 hasConcept C2777701055 @default.
• W4285384608 hasConcept C2780352672 @default.
• W4285384608 hasConcept C2781053074 @default.
• W4285384608 hasConcept C44249647 @default.
• W4285384608 hasConcept C50382708 @default.
• W4285384608 hasConcept C509974204 @default.
• W4285384608 hasConcept C71924100 @default.
• W4285384608 hasConcept C86803240 @default.
• W4285384608 hasConcept C8891405 @default.
• W4285384608 hasConceptScore W4285384608C121608353 @default.
• W4285384608 hasConceptScore W4285384608C126322002 @default.
• W4285384608 hasConceptScore W4285384608C126894567 @default.
• W4285384608 hasConceptScore W4285384608C143998085 @default.
• W4285384608 hasConceptScore W4285384608C146357865 @default.

• next